Elicio Therapeutics, Inc. (ELTX)
About Elicio Therapeutics, Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $2.3M
- Net income
- -$39.6M
- Total assets
- $25.9M
- Market cap
- $78.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating income
- -$37.7M
- Income tax
- $0
- Net income
- -$39.6M
- EPS (basic)
- $-2.58
- EPS (diluted)
- $-2.58
Balance sheet
- Total assets
- $25.9M
- Current assets
- $19.3M
- Total liabilities
- $24.2M
- Current liabilities
- $8.1M
- Shareholders’ equity
- $1.6M
Cash flow
- Operating cash flow
- -$37.0M
- Investing cash flow
- -$16.0K
- Financing cash flow
- $36.7M
- Net cash flow
- -$225.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $78.8M
- EPS (diluted)
- $-2.58
- Shares outstanding
- 84.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 2, 2023
Elicio Therapeutics, Inc. (ELTX) Stock Price
- Reported a net loss of $39.6M in FY2022.
- Trading 80% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Elicio Therapeutics, Inc..
Write a review
News about Elicio Therapeutics, Inc.
News & sentiment via Polygon.io
Elicio Therapeutics, Inc.: frequently asked questions
Is Elicio Therapeutics, Inc. an American company?
Elicio Therapeutics, Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Elicio Therapeutics, Inc. headquartered?
Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States.
Is Elicio Therapeutics, Inc. publicly traded?
Yes — Elicio Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ELTX on the NASDAQ.
What does Elicio Therapeutics, Inc. do?
Elicio Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
